near resolut opioid thought
jnj result better expect stock trade view
nearli much given result versu
 healthcar provid earli commentari
outlook suggest ep growth would like line sale growth
rais ep maintain
ep
outstand legal liabilitiesmainli includ opioid talchav overhang
stock varieti product liabil receiv
attent press risperd last night wall street journal link report
drug distributor work toward deal billion deal year resolv
opioid litig note involv discuss morn
bloomberg link alleg offer pay billion settl claim presum
also multi-year period
would view billion payment resolv opioid favor would believ
would market especi multi-year period billion repres
quarter js free cash flow would lift least one major overhang stock
remov level discount view share
could trade think sinc share trade
averag pe ntm in-lin overal today stock
trade discount ntm basi use quarter pre-tax profit split
proxi includ signific asset sale gain pharma repres
medic devic consum use consensu estim pharma
multipl today vari greatli med-tech lower end
seem us reason given growth consum stock averag eas
litig overhang could warrant valuat stock closer blend pe
rang view would also incorpor valuat
pharma divis toward higher end group key risk howev
sustain pharma pe gener given polit environ drug price
rhetor rate equal weight price target pe ep
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
equal weight continu like jnj
continu innov bode well
longer term howev believ litig concern
like remain overhang stock along
concern regard near-term biosimilar
gener pressur also believ street
ep estim may high rate share equal
upsid driver includ capit deploy drive
faster growth greater success new drug
outcom greater margin expans
downsid risk includ drug price
pharmaceut pipelin lower expect
clinic commerci success medic devic
action drug/devic recal margin eros
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
sale street estim driven strength pharmaceut
medic devic ep street estim
estim rais full-year organ sale guidanc
adjust ep guidanc
net/net despit impress beat rais maintain equal weight
litig may remain overhang stock
addit detail quarter
million except per share data chang sale constant currenc underli basi unless otherwis note
 rais full-year organ sale guidanc adjust ep
guidanc
sever js drug continu report robust sale growth includ stelara
darzalex imbruvica tremfya invega/sustenna
simponi/simponi aria erleada uptravi
opsumit also expect continu grow pharma franchis
market
medic devic organ growth continu improv exclud
impact benefit buy-in ahead japanes consumpt tax
strongest year
 provid earli commentari note expect grow ep
least line revenu growth
 continu face pressur gener biosimilar remicad
 zytiga velcad
 continu lose share knee albeit less
knee growth help off-set declin
minim increment updat given regard litig remain
overhang stock make addit litig accrual
gross margin sale y/i
sg sale y/i reflect js cost contain
measur priorit spend
 sale y/i primarili driven invest medic
devic particularli robotics/digit surgeri program key growth platform
oper margin y/i
adjust tax rate y/i driven adjust exist tax
adjust ep street estim estim
 rais full-year organ sale growth guidanc constant currenc sale growth guidanc
full-year rais report sale growth guidanc rais
manag also rais low-end full-year tax rate guidanc full-year adjust ep
expect rais
manag plan releas formal guidanc along result januari howev manag provid
commentari around segment note expect pharma deliv above-market growth continu sale
momentum medic devic improv profit portfolio optim consum expect incom
approxim half level record effect tax rate rang net/net ep growth
revenu breakdown divis
pre-tax profit breakdown divis
discuss herein
 js segment sale includ drug immun system
cardiovascular diseas metabol disord
pharmaceut sale total billion oper basi
gener zytiga impact ww pharma growth growth
led
pharma growth
immunolog oncolog
neurosci infecti diseas sale growth modest
cardiovascular/metabol sale declin reflect xarelto increas
medicar util higher donut hole util rebat chang
competit pressur label chang procrit/eprex biosimilar competit
growth
immunolog sale total billion constant currenc basi
strong doubl digit growth stelara tremfya simponi/simponi aria off-set
declin remicad
stelara continu robust growth trajectori increas quarter driven
strong uptak crohn diseas expect continu growth ahead stelara
septemb european commiss approv stelara treatment moder
sever activ ulcer coliti
tremfya sale continu gain share psoriasi market file
fda expand label indic includ adult activ psoriat arthriti
oncolog growth driver though gener competit zytiga
well velcad recent weigh perform said even gener
competit total oncolog sale constant currenc
oncolog growth led darzalex record sale million sale
quarter sale growth includ benefit due one-tim
reimburs adjust posit impact growth intern
us grew imbruvica sale global reflect market
share gain well market growth also comment continu pleas
launch progress erleada
zytiga sale declin global reflect impact gener us
busi offset growth intern velcad sale
also reflect impact gener
neurosci sale constant currenc basi led paliperidon
longact portfolio includ invega sustenna xeplion invega trinza trevicta
constant currenc basi concerta sale risperd
consta sale neruosci sale
provid sale contribut commentari spravato compani anti-depress
drug manag note site certifi rem program
becom spravato treatment center site activ treat
patient treatment resist depress view payor coverag may limit
factor uptak product
pulmonari hypertens sale strong sale uptravi
opsumit off-set lower sale tracleer due gener
infecti diseas sale constant currenc basi
cm sale constant currenc declin function three
key drug portfolio
xarelto sale flattish volum increas off-set rebat due
donut hole rate increas higher medicar util
procrit/eprex sale declin due continu biosimilar competit
invokana/invokamet sale declin due share loss impact safeti
label updat unit state
look ahead expect grow franchis overal
pharma market estim grow around
venou thromboembol vte acut ill
diabet kidney diseas heart failur
hospit type diabet patient
expand use treatment moder
submit
treatment expand pediatr patient age
moder sever plaqu psoriasi
fda
treatment adult activ psoriat arthriti
submit
monthli inject drug regimen
treatment hiv
fda
reduct depress symptom adult
major depress disord suicid
combin regimen newli diagnos stem
cell transplant-elig patient multipl
treatment patient metastat castration-
expand use combin obinutuzumab
adult patient previous untreat cll
combo rituximab waldenstrom
 js medic devic segment sale includ product use orthoped
surgeri intervent solut eye health
total segment sale adjust fx acquisition/divestitur sequenti improv
 note one-tim item larg relat forward buy ahead
consumpt tax chang japan contribut growth manag expect
major sell remaind exclud impact
medic devic busi growth rate
growth driven intervent solut led growth
electrophysiolog well vision ex-japan estim surgic
sale exclud impact asp divestitur orthoped sale growth
improv slightli remain modest
manag note sell day minor posit impact
signific impact expect
orthoped sale increas oper basi increas larg
attribut improv hip trauma along intern growth knee
knee show modest improv rel
hip sale grew oper took share due continu leadership
anterior approach well demand acti primari stem kincis surgic
trauma sale grew oper driven adopt femor neck system
recon nail one-tim rebat reserv adjust contribut almost
adjust one-tim item trauma grew line global market
spine declin less primarili due share loss manag note
continu see stabil perform driven new product viper
prime system mi newli launch conduit interbodi platform eit cellular
titanium print technolog treat degen spine diseas
knee increas oper declin strong growth
ou manag note one-tim influenc trend
rather strong perform manag comment believ market ou
perform due new innov includ attun revis
 compani continu see posit uptak attun revis
launch attun cementless knee quarter
surgeri sale declin oper basi due asp divestitur
organ basi estim sale increas
advanc surgeri deliv growth led growth energi primarili driven
share gain new product aspac biosurgeri grew growth across
region particularli aspac manag note surgiflo market one
month end juli impact growth
gener surgeri growth driven wound closur grew almost reflect
share gain convent barb sutur market growth china addit
manag note launch echelon circular industri first power circular
stapler colorect gastric thorac surgeri
electrophysiolog well double-digit growth cerenovu driven
new ablat advanc cathet product
contribut atrial fibril af procedur growth compani note result
af progress trial attest show cathet ablat less like develop
persist af patient standard antiarrhythm drug year
vision sale growth aid forward buy japan ahead
consumpt tax increas contact lens also contribut growth
manag highlight launch tecni synergi iol surgic vision
 js consum segment sale includ product babi care oral care
beauti over-the-counter women health wound care market
segment grew oper basi impact acquisit
zarbe dr ci labo well divestitur roc babycent busi
adjust net impact transact organ sale us
ou growth earn call manag
comment talc litig insignific impact consum perform
quarter
beauti grew exclud impact dr ci labo roc acquisit
divestitur growth driven neutrogena aveeno well time
promot club channel
over-the-counter grew exclud impact zarbe acquisit
adult tylenol primari contributor sale growth due strength releas
gel tylenol arthriti product zyrtec gain market share though sale declin due
lap retail stock relat competitor suppli disrupt
babi sale exclud impact babycent divestitur sale
declin declin primarili due difficult comparison retail stock
associ johnson babi relaunch us exclud babi relaunch
comparison us babi flat
addit commentari js call pleas see note publish
 kstew call note lot run usual
model pleas see barclay websit link
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
